MCID: ORL015
MIFTS: 56

Oral Squamous Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 11 47 13
Squamous Cell Carcinoma of Mouth 67
 
Mouth Squamous Cell Carcinoma 11

Classifications:



External Ids:

Disease Ontology11 DOID:0050866

Summaries for Oral Squamous Cell Carcinoma

About this section
Disease Ontology:11 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary: Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to oral lichen planus and herpes simplex. An important gene associated with Oral Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways are HIF1Alpha Pathway and Central carbon metabolism in cancer. Affiliated tissues include lung, lymph node and skin, and related mouse phenotypes are pigmentation and liver/biliary system.

Related Diseases for Oral Squamous Cell Carcinoma

About this section

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 246)
idRelated DiseaseScoreTop Affiliating Genes
1oral lichen planus31.2CCND1, CDH1, EGFR, MMP9, TP53, VEGFA
2herpes simplex30.7CDKN2A, EGFR, TP53
3esophagitis30.6AKT1, CASP3, TP53
4plasmacytoma29.2AKT1, CASP3, CCND1, CDH1, CDKN2A, CTNNB1
5esophageal cancer28.4AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
6oral tuberculosis10.9CDH1, TP53
7salivary gland adenoid cystic carcinoma10.9CDKN2A, TP53
8split hand split foot malformation autosomal recessive10.9CDKN2A, HRAS, TP53
9biliary papillomatosis10.8CDKN2A, TP53
10ureter adenocarcinoma10.8CDKN2A, HRAS, TP53
11skeletal tuberculosis10.8CCND1, CDKN2A
12adenofibroma10.8CDKN2A, HRAS, TP53
13kidney sarcoma10.8CDKN1B, TP53, VEGFA
14orbital varix10.8EGFR, PDPN
15peptic ulcer disease10.8EGFR, TP53
1612p12.1 microdeletion syndrome10.8CDH1, CDKN2A, CTNNB1
17bladder verrucous squamous cell carcinoma10.8CCND1, CDKN2A, TP53
18eversion of lacrimal punctum10.8CCND1, EGFR, HRAS
19tic disorder10.8CCND1, EGFR, HRAS
20epithelioid trophoblastic tumor10.8CDKN2A, TP53, VEGFA
21oligodendroglioma10.8CCND1, CDKN2A, TP53
22stampe sorensen syndrome10.8EGFR, TP53, VEGFA
23hemangioma of lung10.8CDH1, HRAS, TP53
24multidrug-resistant tuberculosis10.8CCND1, CDKN1B, TP53
25breast papillary carcinoma10.8EGFR, HRAS, PDPN
26early myoclonic encephalopathy10.8CDKN2A, EGFR, TP53
27distal monosomy 9p10.8EGFR, TP53, VEGFA
28novak syndrome10.8CCND1, EGFR, TP53
29anal squamous cell carcinoma10.8CDKN2A, EGFR, TP53
30fallopian tube carcinoma10.8CDH1, CDKN2A, TP53
31actinic keratosis10.8CDKN2A, EGFR, TP53
32renal pelvis carcinoma10.8EGFR, MMP2, MMP9
33grade iii astrocytoma10.8CDKN2A, EGFR, TP53
34prostate adenoid cystic carcinoma10.8CCND1, EGFR, VEGFA
35extrahepatic bile duct adenocarcinoma10.8CDH1, CTNNB1, TP53
36antidepressant or antipsychotic toxicity or dose selection10.8MMP9, PDPN, TP53
37leydig cell tumor10.8PDPN, VEGFA, VEGFC
38calcaneonavicular coalition10.8EGFR, VEGFA, VEGFC
39angiokeratoma circumscriptum10.8CDKN2A, EGFR, TP53
40verloove vanhorick brubakk syndrome10.7EGFR, TP53, VEGFA
41seminal vesicle tumor10.7CTNNB1, MMP9, VEGFA
42bilateral retinoblastoma10.7CCND1, CDKN1B, CDKN2A, TP53
43ovarian small cell carcinoma10.7CTNNB1, EGFR, TP53
44zellweger-like syndrome without peroxisomal anomalies10.7MMP2, MMP9
45milker's nodule10.7CDH1, CDKN2A, EGFR, TP53
46pharynx cancer10.7CCND1, CDKN1B, CDKN2A, TP53
47rectum malignant melanoma10.7EGFR, HRAS, TP53
48keratopathy10.7MMP1, MMP2, TP53
49ascending colon cancer10.7CCND1, CDKN1B, CDKN2A, TP53
50progesterone-receptor positive breast cancer10.7CCND1, EGFR, TP53

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to oral squamous cell carcinoma

Symptoms for Oral Squamous Cell Carcinoma

About this section

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

About this section

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 463)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CetuximabapprovedPhase 4, Phase 3, Phase 2, Phase 1737205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
2
FluorouracilapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
3
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
4
EverolimusapprovedPhase 4, Phase 1, Phase 21896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
Technetium tc 99m sulfur colloidapprovedPhase 422
Synonyms:
 
Technetium 99m sulfur colloid
Technetium Tc-99m Sulfur Colloid
6
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
7
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
8
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
9
Edetic Acidapproved, vet_approvedPhase 49560-00-4, 62-33-96049
Synonyms:
(ethylenedinitrilo)tetraacetic acid, ion(4−)
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcium Disodium Edetate (JAN)
Calcium Disodium Versenate
Calcium disodium versenate (TN)
 
EDT
EDTA
EDTA, ion(4-)
Edetate Calcium
Edetate calcium disodium (USP)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
acide edetique
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
10
Morphineapproved, investigationalPhase 496057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
11
Cyclosporineapproved, investigational, vet_approvedPhase 491579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
12
AzathioprineapprovedPhase 4165446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
13
Mycophenolic acidapprovedPhase 493924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
14
Mycophenolate mofetilapproved, investigationalPhase 4939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
15
Tacrolimusapproved, investigationalPhase 41074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
16Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17793
17Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
18RadiopharmaceuticalsPhase 4, Phase 2, Phase 1485
19Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14855
20Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14694
21Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
22Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
23Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 222776
24Cholinergic AgentsPhase 4, Phase 33846
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 117734
26Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
27AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 111774
28Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
29AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211287
30Antirheumatic AgentsPhase 4, Phase 3, Phase 1, Phase 210627
31Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 112770
32Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 17171
33Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13615
34AnestheticsPhase 4, Phase 3, Phase 2, Phase 19001
35Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 11588
36MitomycinsPhase 4, Phase 3, Phase 2233
37Analgesics, OpioidPhase 4, Phase 33091
38Anesthetics, GeneralPhase 4, Phase 3, Phase 12787
39Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112806
40Anesthetics, IntravenousPhase 4, Phase 3, Phase 12406
41NarcoticsPhase 4, Phase 33486
42DextransPhase 499
43Chelating AgentsPhase 41365
44Blood SubstitutesPhase 4246
45Pentetic AcidPhase 495
46AnticoagulantsPhase 42516
47Plasma SubstitutesPhase 4233
48Technetium Tc 99m PentetatePhase 416
49Calcineurin InhibitorsPhase 41597
50Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2969

Interventional clinical trials:

(show top 50)    (show all 733)
idNameStatusNCT IDPhase
1Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
2A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
3Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
4Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the LipCompletedNCT00868088Phase 4
5Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
6Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
7Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerRecruitingNCT02287675Phase 4
8Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
9Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4
10TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell CarcinomaUnknown statusNCT01542931Phase 2, Phase 3
11Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
12Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung CarcinomaUnknown statusNCT01947062Phase 3
13Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
14Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
15Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
16S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
17Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
18Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397Unknown statusNCT01466244Phase 3
19Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
20PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
21Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma PatientsCompletedNCT00201383Phase 3
22Chemoprevention Study of Oral Cavity Squamous Cell CarcinomaCompletedNCT00201279Phase 3
23Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck PatientsCompletedNCT01439724Phase 3
24Phase II Trial of Allovectin-7® for Head and Neck CancerCompletedNCT00050388Phase 3
25Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCCCompletedNCT00158652Phase 3
26Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck CancerCompletedNCT00003139Phase 3
27Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCCCompletedNCT00162708Phase 2, Phase 3
28Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RTCompletedNCT01931150Phase 3
29Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck CancerCompletedNCT00101582Phase 3
30Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3
31Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
32Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or LarynxCompletedNCT00004234Phase 3
33Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
34Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During SurgeryCompletedNCT00002670Phase 3
35Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00054561Phase 3
36Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck CancerCompletedNCT00006481Phase 3
37Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003888Phase 3
38Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003592Phase 3
39Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
40Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00003809Phase 3
41Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During SurgeryCompletedNCT00003576Phase 3
42Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck CancerCompletedNCT00064298Phase 3
43Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
44ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresCompletedNCT00404924Phase 3
45Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00608205Phase 3
46Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerCompletedNCT00007631Phase 3
47Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck CancerCompletedNCT00094081Phase 3
48Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
49Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002507Phase 3
50Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck CancerCompletedNCT00004917Phase 3

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

About this section

Anatomical Context for Oral Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

35
Lung, Lymph node, Skin, Endothelial, Salivary gland, Brain, Bone

Animal Models for Oral Squamous Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Oral Squamous Cell Carcinoma:

40 (show all 28)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000118610.0CASP3, CDKN1B, CDKN2A, CTNNB1, EGFR, TP53
2MP:00053709.8AKT1, CDKN1B, CDKN2A, CTNNB1, EGFR, TP53
3MP:00053809.7AKT1, CDH1, CDKN2A, CTNNB1, EGFR, HOPX
4MP:00053829.5CASP3, CCND1, CDKN1B, CTNNB1, EGFR, HRAS
5MP:00028739.4AKT1, CCND1, CDH1, CTNNB1, EGFR, HRAS
6MP:00030129.4CASP3, CDH1, CDKN1B, CDKN2A, CTNNB1, EGFR
7MP:00053679.3CASP3, CDKN1B, CTNNB1, EGFR, HRAS, MMP9
8MP:00053919.3CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1, EGFR
9MP:00053799.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
10MP:00053899.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
11MP:00053849.0AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
12MP:00053909.0AKT1, CASP3, CCND1, CDKN2A, CTNNB1, EGFR
13MP:00020069.0AKT1, CCND1, CDH1, CDKN1B, CDKN2A, CTNNB1
14MP:00053869.0AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
15MP:00053699.0AKT1, CASP3, CDKN1B, CDKN2A, CTNNB1, EGFR
16MP:00107718.8AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
17MP:00053978.8AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
18MP:00036318.8AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
19MP:00053888.7AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
20MP:00053818.5CASP3, CCND1, CDH1, CDKN1B, CDKN2A, CTNNB1
21MP:00053788.5AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
22MP:00053878.4AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
23MP:00107688.2AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
24MP:00053857.9AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
25MP:00053767.8AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

Publications for Oral Squamous Cell Carcinoma

About this section

Articles related to Oral Squamous Cell Carcinoma:

(show top 50)    (show all 2032)
idTitleAuthorsYear
1
SOX4 expression is associated with treatment failure and chemoradioresistance in oral squamous cell carcinoma. (26555193)
2015
2
Osteopontin-integrin I+(v)I^(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma. (25497015)
2015
3
Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo. (26639757)
2015
4
Protease-activated receptor 2 modulates proliferation and invasion of oral squamous cell carcinoma cells. (25912757)
2015
5
Relationship among tobacco habits, human papilloma virus (HPV) infection, p53 polymorphism/mutation and the risk of oral squamous cell carcinoma. (25328301)
2014
6
Role of EZH2 in oral squamous cell carcinoma carcinogenesis. (24424512)
2014
7
Lack of Evidence for Predictive and Prognostic Value of Cyclin D1 Gene Polymorphism CCND1 G870A for Oral Squamous Cell Carcinoma. (24403468)
2014
8
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). (24999729)
2014
9
Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma. (25174622)
2014
10
Stromal myofibroblasts in nonmetastatic and metastatic oral squamous cell carcinoma: An immunohistochemical study. (24250077)
2013
11
High interstitial fluid pressure promotes tumor cell proliferation and invasion in oral squamous cell carcinoma. (24043259)
2013
12
Accumulation of inactive p53 protein in oral squamous cell carcinoma: stabilization by protein interaction. (23331420)
2013
13
Aberrant promoter methylation of PTEN gene among Indian a8"patients with oral squamous cell carcinoma. (23787493)
2013
14
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. (22486898)
2012
15
HOXB7 expression is a prognostic factor for oral squamous cell carcinoma. (22239410)
2012
16
Retrospective Study of Selective Submandibular Neck Dissection versus Radical Neck Dissection for N0 or N1 Necks in Level I Patients with Oral Squamous Cell Carcinoma. (22690218)
2012
17
Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma. (22466643)
2012
18
A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. (22529575)
2011
19
Increased I9Np63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. (21833468)
2011
20
Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis. (21501231)
2011
21
Tumour infiltrating CD25+ FoxP3+ regulatory T cells (Tregs) relate to tumour grade and stromal inflammation in oral squamous cell carcinoma. (21352381)
2011
22
CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. (21117028)
2011
23
Influence of class M1 glutathione S-transferase (GST Mu) polymorphism on GST M1 gene expression level and tumor size in oral squamous cell carcinoma. (20060357)
2010
24
Correlation between the expression of cytokeratin-18-mRNA and invasion and metastasis of oral squamous cell carcinoma]. (19575986)
2009
25
LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma. (20975919)
2009
26
Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. (19300368)
2009
27
Synchronous oral squamous cell carcinoma and extramedullary plasmacytoma of the tonsil. (19570691)
2009
28
Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients. (18312299)
2008
29
Hyaluronan-mediated motility: a target in oral squamous cell carcinoma. (18425326)
2008
30
A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. (18853752)
2008
31
Involvement of CXCL12 and CXCR4 in lymph node metastases and development of oral squamous cell carcinomas. (18781098)
2008
32
Expression and significance of vascular cell adhesion molecule-1 in human oral squamous cell carcinoma]. (19186848)
2008
33
ESE-1 inhibits the invasion of oral squamous cell carcinoma in conjunction with MMP-9 suppression. (18302674)
2008
34
Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. (17622326)
2007
35
Increased expression and activation of matrix metalloproteinase-2 (MMP-2) in O-1N: hamster oral squamous cell carcinoma with high potential lymph node metastasis. (17167983)
2006
36
Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front. (16344911)
2006
37
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. (16271509)
2006
38
Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. (16211297)
2005
39
P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study. (15967043)
2005
40
A role of activated Sonic hedgehog signaling for the cellular proliferation of oral squamous cell carcinoma cell line. (14733907)
2004
41
Mutation and aberrant expression of Caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. (14719121)
2004
42
Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. (12759539)
2003
43
Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma. (14748745)
2003
44
Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma. (12169394)
2002
45
Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. (11854066)
2002
46
Mutational analysis of the candidate tumor suppressor gene ING1 in Indian oral squamous cell carcinoma. (11287275)
2001
47
Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. (11235994)
2000
48
Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. (11098077)
2000
49
Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. (10889925)
2000
50
Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. (9509127)
1997

Variations for Oral Squamous Cell Carcinoma

About this section

Cosmic variations for Oral Squamous Cell Carcinoma:

8 (show top 50)    (show all 340)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM6240EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2369C>Tp.T790M12
2COSM99622NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.4016G>Cp.G1339A12
3COSM44310TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.738G>Ap.M246I12
4COSM10648TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.524G>Ap.R175H12
5COSM11196TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.734G>Tp.G245V12
6COSM763PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1633G>Ap.E545K12
7COSM24802FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2089G>Tp.G697C12
8COSM33692HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.185A>Gp.E62G12
9COSM43947TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.614A>Gp.Y205C12
10COSM44393TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.821T>Cp.V274A12
11COSM498HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.182A>Tp.Q61L12
12COSM764PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1634A>Gp.E545G12
13COSM43582TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.454C>Tp.P152S12
14COSM483HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Tp.G12V12
15COSM29446FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.753C>Tp.H251H12
16COSM44226TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.380C>Tp.S127F12
17COSM99653NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3835C>Tp.R1279C12
18COSM10654TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.637C>Tp.R213*12
19COSM10704TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.844C>Tp.R282W12
20COSM10672TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.577C>Tp.H193Y12
21COSM10941TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.730G>Ap.G244S12
22COSM10656TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.742C>Tp.R248W12
23COSM10728TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.839G>Ap.R280K12
24COSM43635TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.536A>Tp.H179L12
25COSM1667029NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.666C>Ap.C222*12
26COSM44126TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.507G>Ap.M169I12
27COSM10790TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.455C>Tp.P152L12
28COSM43868TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.689C>Tp.T230I12
29COSM12504CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.247C>Tp.H83Y12
30COSM44335TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.958A>Tp.K320*12
31COSM44091TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.746G>Ap.R249K12
32COSM11063TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Tp.M237I12
33COSM1737921CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.124A>Cp.N42H12
34COSM44577TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.921A>Gp.A307A12
35COSM3722007HCN1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.808C>Tp.R270*12
36COSM488HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.37G>Tp.G13C12
37COSM99939NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.5529G>Ap.W1843*12
38COSM10834TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Ap.M237I12
39COSM45099TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.924G>Ap.L308L12
40COSM3724382NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.6738C>Gp.H2246Q12
41COSM521KRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Ap.G12D12
42COSM3724387CASP8upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.415C>Tp.Q139*12
43COSM480HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
44COSM481HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Tp.G12C12
45COSM3723031PHF14upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.344A>Gp.K115R12
46COSM777PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3145G>Ap.G1049S12
47COSM12764EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2569G>Ap.G857R12
48COSM489HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.38G>Tp.G13V12
49COSM10867TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.797G>Ap.G266E12
50COSM11073TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1024C>Tp.R342*12

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

6 (show top 50)    (show all 164)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
141848102460000038000000DeletionOral squamous cell carcinoma
24970611110400000121200000DeletionOral squamous cell carcinoma
35098811121200000130800000DeletionOral squamous cell carcinoma
451497111270000016200000DeletionOral squamous cell carcinoma
557445116340000077100000AmplificationCCND1Oral squamous cell carcinoma
657446116340000077100000AmplificationEMS1Oral squamous cell carcinoma
757448116340000077100000AmplificationFGF3Oral squamous cell carcinoma
857449116340000077100000AmplificationFGF4Oral squamous cell carcinoma
957450116340000077100000AmplificationPPP1CAOral squamous cell carcinoma
1057451116340000077100000AmplificationTAOS1Oral squamous cell carcinoma
1158782116947136769490165AmplificationORAOV1Oral squamous cell carcinoma
12740651314500000DeletionOral squamous cell carcinoma
137417913101700000110300000DeletionOral squamous cell carcinoma
14751701317900000115169878Noncopy numberrandom LOHOral squamous cell carcinoma
1576133132780000055300000DeletionOral squamous cell carcinoma
1676134132780000087700000DeletionOral squamous cell carcinoma
1776220132890000040100000DeletionOral squamous cell carcinoma
1876534133220000040100000DeletionOral squamous cell carcinoma
1976709133550000040100000DeletionOral squamous cell carcinoma
2077109134010000059600000DeletionOral squamous cell carcinoma
2178640135530000073300000DeletionOral squamous cell carcinoma
2279281136860000087700000DeletionOral squamous cell carcinoma
2379539137330000079000000DeletionOral squamous cell carcinoma
2479879137900000087700000DeletionOral squamous cell carcinoma
2580342139000000098200000DeletionOral squamous cell carcinoma
26806291395000000110300000DeletionOral squamous cell carcinoma
27806321395000000115169878DeletionOral squamous cell carcinoma
2880634139500000098200000DeletionOral squamous cell carcinoma
2983034141910000033300000DeletionOral squamous cell carcinoma
3084231142460000033300000DeletionOral squamous cell carcinoma
3185052143780000050900000DeletionOral squamous cell carcinoma
3286340145810000067900000DeletionOral squamous cell carcinoma
3386341145810000073800000DeletionOral squamous cell carcinoma
3487452147380000079300000DeletionOral squamous cell carcinoma
358913315119000000Noncopy numberrandom LOHOral squamous cell carcinoma
3690246152070000040100000DeletionOral squamous cell carcinoma
3791779153360000040100000DeletionOral squamous cell carcinoma
3891783153360000044800000DeletionOral squamous cell carcinoma
3992363154010000049500000DeletionOral squamous cell carcinoma
4092861154480000049500000DeletionOral squamous cell carcinoma
4193371155290000072700000DeletionOral squamous cell carcinoma
4295627157830000089100000DeletionOral squamous cell carcinoma
4395629157830000098500000DeletionOral squamous cell carcinoma
4410675417116000000DeletionOral squamous cell carcinoma
4510683117124000000Noncopy numberrandom LOHOral squamous cell carcinoma
4610690717181195210DeletionOral squamous cell carcinoma
47106970171070000050200000DeletionOral squamous cell carcinoma
48109058172400000081195210Noncopy numberrandom LOHOral squamous cell carcinoma
49112186173810000057600000DeletionOral squamous cell carcinoma
50114590175020000070900000DeletionOral squamous cell carcinoma

Expression for genes affiliated with Oral Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for genes affiliated with Oral Squamous Cell Carcinoma

About this section

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 45)
idSuper pathwaysScoreTop Affiliating Genes
19.9CDKN2A, TP53, VEGFA, VEGFC
29.9AKT1, EGFR, HRAS, TP53
39.9AKT1, CDH1, EGFR, HRAS
49.9AKT1, CCND1, CDKN1B, EGFR
59.9CCND1, MMP1, MMP2, MMP9
69.9AKT1, CCND1, CDH1, CTNNB1
79.8EGFR, MMP1, MMP2, MMP9
89.8CCND1, CDH1, CTNNB1, HRAS, TP53
99.8CCND1, CDH1, CTNNB1, MMP2, MMP9
10
Show member pathways
9.8AKT1, CCND1, CDKN1B, EGFR, HRAS
11
Show member pathways
9.8AKT1, CCND1, CDKN1B, EGFR, HRAS
129.8CDKN2A, CTNNB1, MMP2, TP53, VEGFA
139.7AKT1, CCND1, CTNNB1, HRAS, TP53
149.7CASP3, EGFR, HRAS, VEGFA, VEGFC
15
Show member pathways
9.7AKT1, CTNNB1, HRAS, VEGFA, VEGFC
169.7CASP3, CCND1, CDKN1B, CDKN2A, HRAS, TP53
179.7AKT1, CASP3, EGFR, MMP2, MMP9
18
Show member pathways
9.6AKT1, CCND1, CDKN1B, EGFR, HRAS, TP53
199.6CASP3, CCND1, CDKN1B, EGFR, MMP9, TP53
209.6AKT1, CCND1, CDKN2A, CTNNB1, HRAS, TP53
21
Show member pathways
9.6AKT1, CASP3, CCND1, CDKN1B, EGFR, TP53
22
Show member pathways
9.6AKT1, CASP3, CDKN1B, HRAS, MMP1, TP53
23
Show member pathways
9.6AKT1, CCND1, CTNNB1, EGFR, HRAS, MMP2
249.6AKT1, CASP3, EGFR, HRAS, MMP2, MMP9
25
Show member pathways
9.5AKT1, CASP3, CTNNB1, EGFR, HRAS, TP53
269.5AKT1, CASP3, CDKN1B, CTNNB1, MMP9, VEGFA
27
Show member pathways
9.5AKT1, CASP3, CCND1, CDKN1B, HRAS, MMP9
28
Show member pathways
9.4AKT1, CASP3, CDH1, CTNNB1, HRAS, TP53
29
Show member pathways
9.4AKT1, CDH1, CTNNB1, EGFR, HRAS, VEGFA
30
Show member pathways
9.4AKT1, CCND1, CDKN1B, CDKN2A, EGFR, HRAS
319.3AKT1, CCND1, CDKN1B, CDKN2A, CTNNB1, EGFR
329.3AKT1, CCND1, CDKN1B, EGFR, HRAS, TP53
339.3AKT1, CASP3, CCND1, CDKN1B, HRAS, MMP2
34
Show member pathways
9.3AKT1, CCND1, CDKN1B, CTNNB1, EGFR, HRAS
35
Show member pathways
9.3AKT1, CASP3, CCND1, CDH1, CTNNB1, EGFR
369.3AKT1, CASP3, CCND1, CDKN1B, CTNNB1, EGFR
379.2CASP3, CCND1, CDKN1B, CDKN2A, EGFR, HRAS
38
Show member pathways
9.2AKT1, CCND1, CDH1, CDKN1B, CDKN2A, CTNNB1
39
Show member pathways
9.1AKT1, CASP3, CCND1, CTNNB1, EGFR, HRAS
409.1CCND1, CDH1, CDKN2A, EGFR, HRAS, MMP1
419.1AKT1, CASP3, CCND1, CDH1, CTNNB1, EGFR
429.0AKT1, CASP3, CCND1, CTNNB1, EGFR, HRAS
438.8AKT1, CASP3, CCND1, CDH1, CTNNB1, EGFR
44
Show member pathways
8.7AKT1, CCND1, CDKN1B, CDKN2A, EGFR, HRAS
458.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

GO Terms for genes affiliated with Oral Squamous Cell Carcinoma

About this section

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1flotillin complexGO:001660010.8CDH1, CTNNB1
2catenin complexGO:001634210.8CDH1, CTNNB1
3apical junction complexGO:004329610.8CDH1, CTNNB1
4cytoplasmGO:00057378.2AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.9AKT1, EGFR
2mitotic G1 DNA damage checkpointGO:003157110.8CCND1, TP53
3cellular response to indole-3-methanolGO:007168110.7CDH1, CTNNB1
4cellular response to lithium ionGO:007128510.7CDH1, CDKN1B, CTNNB1
5positive regulation of vascular smooth muscle cell proliferationGO:190470710.7MMP2, MMP9
6response to X-rayGO:001016510.7CASP3, CCND1, TP53
7negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.7CASP3, CDKN1B, CDKN2A
8positive regulation of blood vessel endothelial cell migrationGO:004353610.7AKT1, VEGFA, VEGFC
9response to UV-AGO:007014110.7AKT1, CCND1, EGFR
10ERBB2 signaling pathwayGO:003812810.6AKT1, EGFR, HRAS
11collagen catabolic processGO:003057410.5MMP1, MMP2, MMP9
12positive regulation of MAP kinase activityGO:004340610.5EGFR, HRAS, VEGFA
13positive regulation of neuron apoptotic processGO:004352510.5CASP3, CTNNB1, TP53
14cellular response to growth factor stimulusGO:007136310.5AKT1, CTNNB1, EGFR
15cell cycle arrestGO:000705010.4CDKN1B, CDKN2A, HRAS, TP53
16Ras protein signal transductionGO:000726510.4CDKN2A, HRAS, TP53
17extracellular matrix disassemblyGO:002261710.4CDH1, MMP1, MMP2, MMP9
18response to organic cyclic compoundGO:001407010.4CASP3, CCND1, CDKN1B, EGFR
19positive regulation of epithelial cell proliferationGO:005067910.3EGFR, HRAS, VEGFA, VEGFC
20cellular response to DNA damage stimulusGO:000697410.3AKT1, CASP3, CCND1, TP53
21response to organic substanceGO:001003310.3AKT1, CASP3, CCND1, CDH1
22lung developmentGO:003032410.2CTNNB1, EGFR, PDPN, VEGFA
23positive regulation of protein phosphorylationGO:000193410.1AKT1, CCND1, EGFR, HRAS, MMP9, VEGFA
24positive regulation of neuroblast proliferationGO:000205210.1CTNNB1, VEGFA, VEGFC
25positive regulation of apoptotic processGO:004306510.0AKT1, CASP3, CTNNB1, MMP9, TP53
26response to estradiolGO:003235510.0CASP3, CCND1, CDKN1B, CTNNB1, EGFR
27single organismal cell-cell adhesionGO:001633710.0CDH1, CRNN, CTNNB1, EGFR, PDPN
28response to hypoxiaGO:00016669.8CASP3, CDKN1B, MMP2, VEGFA
29negative regulation of cell proliferationGO:00082859.8CDKN1B, CDKN2A, CTNNB1, HRAS, TP53, VEGFC
30negative regulation of apoptotic processGO:00430669.8AKT1, CASP3, CDKN1B, EGFR, MMP9, TP53
31cell proliferationGO:00082839.6AKT1, CTNNB1, EGFR, HRAS, PDPN, TP53
32positive regulation of cell proliferationGO:00082849.5CCND1, CDKN1B, CTNNB1, EGFR, HRAS, VEGFA
33response to drugGO:00424939.3CASP3, CCND1, CDH1, CDKN1B, CTNNB1, VEGFC

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nitric-oxide synthase regulator activityGO:003023510.7AKT1, EGFR
2cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.5CASP3, CDKN1B, CDKN2A
3protein phosphatase bindingGO:001990310.1CDKN1B, CTNNB1, EGFR, TP53
4enzyme bindingGO:00198999.7AKT1, CCND1, CTNNB1, EGFR, TP53
5protein kinase bindingGO:00199019.3AKT1, CCND1, CDKN2A, CTNNB1, EGFR, TP53

Sources for Oral Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet